Valuation: Viyash Scientific Limited

Market Cap 111B 1.16B 1.01B 954M 872M 1.63B 1.64B 11.45B 4.44B 56.44B 4.34B 4.24B 183B P/E 2027 *
36.2x
P/E 2028 * 21.9x
Enterprise Value 111B 1.16B 1.01B 954M 872M 1.63B 1.64B 11.45B 4.44B 56.44B 4.34B 4.24B 183B EV / Sales 2027 *
2.84x
EV / Sales 2028 * 2.48x
Free-Float
32.97%
Yield 2027 *
-
Yield 2028 * -
1 day-3.00%
1 week+0.51%
Current month-6.71%
1 month-9.79%
3 months-9.46%
6 months+30.19%
Current year+18.21%
1 week 245
Extreme 245
262.5
1 month 236.85
Extreme 236.85
279.8
Current year 178.4
Extreme 178.4
297.9
1 year 178.4
Extreme 178.4
297.9
3 years 88.39
Extreme 88.39
297.9
5 years 61.8
Extreme 61.8
297.9
10 years 42.45
Extreme 42.45
336.4
Manager TitleAgeSince
Chief Executive Officer 62 15/12/2025
Director of Finance/CFO - 31/12/2025
Chief Tech/Sci/R&D Officer - 04/02/2026
Director TitleAgeSince
Chairman 78 24/08/2025
Director/Board Member 67 24/08/2020
Director/Board Member 57 10/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
-3.00%+0.51%+24.49%+165.68% 1.16B
-1.64%+1.16%+54.09%+109.07% 1,026B
-0.01%+0.71%+52.44%+67.71% 649B
-0.05%+0.98%+19.08%+73.55% 468B
-0.18%+0.44%+39.59%+45.38% 352B
+0.75%+2.24%+21.25%+28.24% 271B
-0.30%-0.11%+10.74%+10.90% 256B
-1.01%+7.90%+41.59%+51.70% 220B
-0.85%+2.50%+32.32%+101.80% 188B
-1.44%-11.12%-33.17%-61.03% 170B
Average -0.41%+1.75%+26.24%+59.30% 360.03B
Weighted average by Cap. +0.01%+1.26%+36.24%+65.82%

Financials

2027 *2028 *
Net sales 38.99B 407M 357M 336M 307M 574M 578M 4.03B 1.56B 19.88B 1.53B 1.5B 64.46B 44.68B 466M 409M 385M 352M 658M 662M 4.62B 1.79B 22.78B 1.75B 1.71B 73.86B
Net income 3.44B 35.89M 31.5M 29.61M 27.08M 50.59M 50.97M 356M 138M 1.75B 135M 132M 5.68B 5.4B 56.32M 49.43M 46.47M 42.48M 79.39M 79.98M 558M 216M 2.75B 212M 207M 8.92B
Net Debt - -
Logo Viyash Scientific Limited
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Employees
2,900
Date Price Change Volume
24/09/26 246.05 -3.00% 64,242
23/09/26 ₹253.65 +0.83% 68,580
22/09/26 ₹251.55 -0.10% 403,837
21/09/26 ₹251.80 +0.76% 74,647
18/09/26 ₹249.90 +2.08% 70,642
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
253.65INR
Average target price
322.25INR
Spread / Average Target
+27.05%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VIYASH Stock